<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059448</url>
  </required_header>
  <id_info>
    <org_study_id>20090402</org_study_id>
    <nct_id>NCT01059448</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of AMG 827 in Subjects With RA</brief_title>
  <official_title>A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This is an extension study for subjects who participated in Protocol 20090061 (NCT00950989).
      All subjects in this study will receive a 210mg injection of AMG827 for treatment for their
      Rheumatoid Arthritis for up to 5 years.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of long-term exposure with AMG 827 is subjects with rheumatoid arthritis.</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of AMG 827 as measured by the proportion of subjects achieving an American College of Rheumatology (ACR) 20, 50, and 70 response</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of AMG 827 as measured by the change in Disease Activity Score 28 joint (DAS28) score</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of AMG 827 as measured by the proportion of subjects with DAS28&lt;2.6</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of AMG 827 as measured by the DAS28 score</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the efficacy of AMG 827 as measured by the ACR individual components</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment on patient-reported outcomes, including the Medical Outcomes Short Form-36 (SF-36), Medical Outcomes Study (MOS) Sleep Scale, and Health Assessment Questionnaire Disability Index (HAQ-DI)</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of subjects who develop anti-AMG 827 anti-bodies</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore lipid profiles in subjects receiving AMG 827</measure>
    <time_frame>5 years of treatment with AMG 827</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>210mg AMG 827</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 827 210mg at baseline, week 1, week2, and every 2 weeks thereafter</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 827</intervention_name>
    <description>AMG 827 210 mg</description>
    <arm_group_label>210mg AMG 827</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has provided informed consent.

          -  Subject was randomized into study 20090061 and completed the week 16 evaluation.

          -  Negative test for hepatitis B virus (HBV) surface antigen, hepatitis C virus (HCV)
             antibody, and/or human immunodeficiency virus (HIV) in subjects if clinically
             indicated (eg, known recent exposure) in the opinion of the investigator.

          -  Subject must test negative for Tuberculosis.

        Exclusion Criteria:

          -  Subject had any SAE reported during 20090061 that was considered to be related to IP.

          -  Subject is currently experiencing an infection of CTCAE grade 2 (if requiring oral
             antibiotics) or higher. Subject is ineligible until the infection is resolved in the
             opinion of the investigator.

          -  For subjects with &gt; 4 weeks between the week 16 visit of 20090061 and the planned
             first IP dose in 20090402, subject has laboratory abnormalities at screening,
             including:

          -  Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT); &gt;1.5x
             upper limit of normal)

          -  Serum total bilirubin ≥1.5 mg/dL

          -  Hemoglobin &lt; 11 g/dL

          -  Platelet count &lt; 125,000 /mm3

          -  White blood cell count &lt; 3,000 cells/mm3

          -  Absolute neutrophil count &lt; 2000/mm3

          -  Estimated creatinine clearance &lt; 50 mL/min (Cockroft-Gault formula, central lab will
             calculate value and provide to sites)

          -  Subject has a significant concurrent medical conditions, including:

          -  Type 1 diabetes

          -  Poorly controlled type 2 diabetes (Hemoglobin A1c &gt; 8.5)

          -  Symptomatic heart failure (New York Heart Association class II, III, or IV)

          -  Myocardial infarction within the last year

          -  Current or history of unstable angina pectoris within the last year

          -  Uncontrolled hypertension as defined by resting blood pressure &gt; 150/90 mmHg prior to
             first IP dose (confirmed by a repeat assessment)

          -  Severe chronic pulmonary disease (eg, requiring oxygen therapy)

          -  Major chronic inflammatory disease or connective tissue disease other than rheumatoid
             arthritis (eg, systemic lupus erythematosus), with the exception of secondary
             Sjögren's syndrome

          -  Multiple sclerosis or any other demyelinating disease

          -  Active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or
             melanoma, or history of cancer (except successfully treated in situ cervical cancer or
             squamous or basal cell carcinoma of the skin)

          -  Any condition that, in the opinion of the investigator, might cause this study to be
             detrimental to the subject

          -  Subject is pregnant or breast feeding, or planning to become pregnant while enrolled
             in the study, up to the subject's last study visit including the follow-up period.

          -  Female subject is not willing to abstain from sexual intercourse or use 2 highly
             effective forms of birth control for the duration of the study and at least 40 days
             after the last dose (except women at least 3 years postmenopausal or surgically
             sterile). Highly effective methods of birth control for women include but are not
             limited to birth control pills, Depo Provera® injections, contraceptive implants, or
             occlusive cap (barrier method) in combination with barrier methods used by the man.

          -  Male subject is not willing to abstain from sexual intercourse or use 2 highly
             effective forms of birth control for the duration of the study, plus an additional 16
             weeks after the last dose (except for men who are surgically sterile or whose female
             partners are at least 3 years postmenopausal or surgically sterile). Highly effective
             methods of birth control include but are not limited to a condom in combination with
             hormonal birth control or barrier methods used by the woman.

          -  Male subject (including vasectomised males) with a pregnant female partner is not
             willing to use effective methods to ensure that an unborn child is not exposed to AMG
             827 via semen. Effective methods to ensure that an unborn child is not exposed to AMG
             827 via semen include condoms or abstinence.

          -  Subject has used any of the following within 14 days prior to IP initiation

          -  Non-biologic disease-modifying anti-rheumatic drugs (DMARD) other than as allowed in
             20090061

          -  Intra-articular, intramuscular, or intravenous corticosteroids, including
             adrenocorticotropic hormone

          -  Subject has used any of the following within 3 months prior to IP initiation

          -  Leflunomide

          -  Live vaccines

          -  Commercially available or experimental biologic DMARD except for AMG 827

          -  Subject has received gold therapy within 6 months prior to IP initiation.

          -  Subject received another investigational agent (other than AMG 827) or participated in
             an investigational device study subsequent to 20090061.

          -  Other investigational procedures are excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rock Island</city>
        <state>Illinois</state>
        <zip>61201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3N 0K6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 11</city>
        <zip>148 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bauska</city>
        <zip>3901</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daugavpils</city>
        <zip>5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liepaja</city>
        <zip>3400</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tijuana</city>
        <state>Baja Calif</state>
        <zip>22010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito F</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito F</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morelia</city>
        <state>MichoacÃ¡n</state>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Potosi</city>
        <state>San Luis P</state>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-356</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>ToruÅ&quot;</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zyrardow</city>
        <zip>96-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merseyside</city>
        <zip>L49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <disposition_first_submitted>April 6, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 27, 2015</disposition_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amgen</keyword>
  <keyword>RA</keyword>
  <keyword>AMG 827</keyword>
  <keyword>20090061</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

